The Current Ratio as of September 2024 (TTM) for Cellectar Biosciences, Inc. (CLRB) is 2.54

According to Cellectar Biosciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.54. This represents a change of 86.91% compared to the average of 1.36 of the last 4 quarters.

Cellectar Biosciences, Inc. (CLRB) Historical Current Ratio (quarterly & annually)

How has CLRB Current Ratio performed in the past?

The mean historical Current Ratio of Cellectar Biosciences, Inc. over the last ten years is 6.05. The current 2.54 Current Ratio has changed 4.11% with respect to the historical average. Over the past ten years (40 quarters), CLRB's Current Ratio was at its highest in in the December 2020 quarter at 16.26. The Current Ratio was at its lowest in in the June 2014 quarter at 0.49.

Cellectar Biosciences, Inc. (CLRB) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cellectar Biosciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cellectar Biosciences, Inc. (CLRB) Average Current Ratio

How has CLRB Current Ratio performed in the past?

The current Current Ratio of Cellectar Biosciences, Inc. (CLRB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cellectar Biosciences, Inc. (CLRB) Current Ratio vs. Peers

How is CLRB’s Current Ratio compared to its peers?

Cellectar Biosciences, Inc.’s Current Ratio is less than Diffusion Pharmaceuticals Inc. (0), less than Monopar Therapeutics Inc. (10.96), less than Pulmatrix, Inc. (6.59), less than Tenax Therapeutics, Inc. (6.33), less than Bio-Path Holdings, Inc. (6.10), greater than Catalyst Biosciences, Inc. (1.67), greater than Capricor Therapeutics, Inc. (0), greater than NextCure, Inc. (1.37), less than Longboard Pharmaceuticals, Inc. (8.35), less than Lumos Pharma, Inc. (20.95), less than ImmunoCellular Therapeutics, Ltd. (4.23), greater than Bolt Biotherapeutics, Inc. (0), less than Applied Molecular Transport Inc. (4.28), less than Aileron Therapeutics, Inc. (4.99), less than Benitec Biopharma Inc. (4.69), less than null (4.18),

Build a custom stock screener for Cellectar Biosciences, Inc. (CLRB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectar Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cellectar Biosciences, Inc. (CLRB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cellectar Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.